SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate

SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate

Peritoneal dialysis (PD) is limited by glucose-mediated peritoneal membrane (PM) fibrosis, angiogenesis, and ultrafiltration failure. Influencing PM integrity by pharmacologically targeting sodium-dependent glucose transporter (SGLT)-mediated glucose uptake has not been studied. In this study, wildt...

Full description

Bibliographic Details
Main Authors:	Michael S. Balzer, Song Rong, Johannes Nordlohne, Jan D. Zemtsovski, Sonja Schmidt, Britta Stapel, Maria Bartosova, Sibylle von Vietinghoff, Hermann Haller, Claus P. Schmitt, Nelli Shushakova
Format:	Article
Language:	English
Published:	MDPI AG 2020-11-01
Series:	Biomolecules
Subjects:	peritoneal dialysis (PD) sodium-dependent glucose transport SGLT inhibition dapagliflozin peritoneum mesothelial cell
Online Access:	https://www.mdpi.com/2218-273X/10/11/1573

Similar Items

SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2
by: Ying Zhou, et al.
Published: (2019-01-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

Peritoneal Dialysis and Its Local and Systemic Complications: From the Bench to the Clinic
by: Janusz Witowski, et al.
Published: (2020-02-01)

Ameliorative role of SIRT1 in peritoneal fibrosis: an in vivo and in vitro study
by: Yanhong Guo, et al.
Published: (2021-04-01)

Management of Diabetes Associated with Nephrotic Syndrome: Therapeutic Potential of Dapagliflozin for Protracted Volume Retention
by: Toshimi Imai, et al.
Published: (2015-11-01)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
by: Julio Rosenstock, et al.

Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors
by: Mie K. Eickhoff, et al.
Published: (2019-05-01)

Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
by: Hyun A Cho, et al.
Published: (2017-06-01)

Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion
by: Milton Packer
Published: (2019-10-01)

SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
by: Dustin M. Lee, et al.
Published: (2018-04-01)

Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial
by: Riobaldo M. R. Cintra, et al.
Published: (2019-07-01)

Class effects of SGLT2 inhibitors on cardiorenal outcomes
by: Aaron Y. Kluger, et al.
Published: (2019-08-01)

Use systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans
by: Yasong eLu, et al.
Published: (2014-12-01)

With Great Age Comes Great Metastatic Ability: Ovarian Cancer and the Appeal of the Aging Peritoneal Microenvironment
by: Elizabeth I. Harper, et al.
Published: (2018-07-01)

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
by: Olga Yuryevna Sukhareva, et al.
Published: (2016-01-01)

Peritoneal Dialysis and Its Local and Systemic Complications: From the Bench to the Clinic.
Published: (2020)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
by: Simes BC, et al.
Published: (2019-10-01)

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
by: Chang Hee Jung, et al.
Published: (2014-08-01)

Inhibition of Sodium-GlucoseCotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease
by: Daniel Rodriguez, et al.
Published: (2015-12-01)

Experimental intraperitoneal injection of alcohol in rats: Peritoneal findings and histopathology
by: Hyun Sin In, et al.
Published: (2014-01-01)

SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
by: Guntram Schernthaner, et al.
Published: (2019-06-01)

Aberrant Wnt/Beta-Catenin Pathway Activation in Dialysate-Induced Peritoneal Fibrosis
by: Yuanyuan Guo, et al.
Published: (2017-10-01)

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
by: Avgerinos I, et al.
Published: (2019-12-01)

The Peritoneum: Beyond the Tissue – A Review
by: Andres Isaza-Restrepo, et al.
Published: (2018-06-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury
by: Sarayut Lahnwong, et al.
Published: (2020-06-01)

Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy
by: Mumin Alper Erdogan, et al.
Published: (2018-06-01)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
by: Kuecker CM, et al.
Published: (2016-02-01)

Analysis of efficacy of SGLT2 inhibitors using semi-mechanistic model
by: Oleg eDemin Jr, et al.
Published: (2014-10-01)

Keratinocyte Growth Factor Combined with a Sodium Hyaluronate Gel Inhibits Postoperative Intra-Abdominal Adhesions
by: Guangbing Wei, et al.
Published: (2016-09-01)

Metalloproteinases in Ovarian Cancer
by: Preston Carey, et al.
Published: (2021-03-01)

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
by: Anna Solini, et al.
Published: (2017-10-01)

Selected indices of peritoneal fibrosis in patients undergoing peritoneal dialysis
by: Józef Penar, et al.
Published: (2009-04-01)

Differential diagnosis and treatment of primary peritoneal cancer and mesothelioma
by: Amir G. Abdullaev, et al.
Published: (2021-02-01)

Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan
by: Jung-Fu Chen, et al.
Published: (2020-11-01)

Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction
by: Nannan Zhang, et al.
Published: (2019-08-01)

The Mesothelial Origin of Carcinoma Associated-Fibroblasts in Peritoneal Metastasis
by: Angela Rynne-Vidal, et al.
Published: (2015-09-01)

Laparoscopic Peritoneal Wash Cytology-Derived Primary Human Mesothelial Cells for In Vitro Cell Culture and Simulation of Human Peritoneum
by: Myriam Holl, et al.
Published: (2021-02-01)

Peritoneal borderline cystoadenocarcinoma
by: Manoel João Batista Castello Girão, et al.

ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial)
by: Pankaj Jariwala, MD, DNB, DNB, MNAMS, FACC, FSCAI, et al.
Published: (2021-09-01)